Announcements Trials
Browse Landscape

Phase

Phase 1/2 6Phase 2 3

Status

Completed 7Terminated 3Recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1Gastrointestinal 1

Conditions

Sarcoma, Ewing 1Sarcoma 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Adenocarcinoma 1

Interventions

Cyclophosphamide 166Docetaxel 154Bevacizumab 153Carboplatin 148Gemcitabine 146Cisplatin 146pembrolizumab 142Radiotherapy 135Paclitaxel 132Capecitabine 122Rituximab 115Oxaliplatin 104Fluorouracil 103Nivolumab 94Irinotecan 85Doxorubicin 85Pemetrexed 83Leucovorin 82Dexamethasone 82fludarabine 74fludarabine phosphate 72Bortezomib 69Etoposide 67Erlotinib Hydrochloride 66Cetuximab 65Methotrexate 58Trastuzumab 56Cytarabine 54Lenalidomide 50Everolimus 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Terminated × ganitumab × Clear all
NCT01318642 2024-11-08

Ganitumab in Locally Advanced Unresectable Adenocarcinoma of the Pancreas

NantBioScience, Inc.

Phase 2 Terminated
10 enrolled 10 charts
Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

NCT04129151 2024-08-01

Palbociclib + Ganitumab In Ewing Sarcoma

Dana-Farber Cancer Institute

Phase 2 Terminated
10 enrolled 15 charts
Sarcoma

Recurrence, Sarcoma, Sarcoma, Ewing

NCT00718523 2016-01-12

Study of Adding AMG 479 to First Line Chemotherapy in Patients With Optimally Debulked Epithelial Ovarian Cancer

Translational Research in Oncology

Phase 2 Terminated
170 enrolled 20 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡